Cargando…

Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model

The objective of this study was to quantify the direct medical resources used and the corresponding burden of disease in the treatment of patients with schizophrenia. Because low-frequency administration (LFA) of risperidone guarantees adherence during treatment intervals and offers fewer opportunit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furiak, Nicolas M, Gahn, James C, Klein, Robert W, Camper, Stephen B, Summers, Kent H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514336/ https://www.ncbi.nlm.nih.gov/pubmed/23157721 http://dx.doi.org/10.1186/1744-859X-11-29

Ejemplares similares

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
por: Furiak, Nicolas M, et al.
Publicado: (2009)

The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial
por: Wang, Congjie, et al.
Publicado: (2017)

Antipsychotic medication and tobacco use among outpatients with schizophrenia: a cross-sectional study
por: Wijesundera, Hiranya, et al.
Publicado: (2014)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study
por: Bahta, Merhawi, et al.
Publicado: (2021)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka, Michal, et al.
Publicado: (2015)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study
por: Roussidis, Andreas, et al.
Publicado: (2013)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
por: Geitona, Maria, et al.
Publicado: (2008)

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Severity in schizophrenia patients receiving atypical antipsychotic medications
por: Alam Fatmi1j, Syed Meraj, et al.
Publicado: (2022)

Pharmacy switch of antipsychotic medications: patient’s perspective
por: Murawiec, Slawomir, et al.
Publicado: (2015)

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study
por: Hashimoto, Naoki, et al.
Publicado: (2015)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Adjuvant low-frequency rTMS in treating auditory hallucinations in recent-onset schizophrenia: a randomized controlled study investigating the effect of high-frequency priming stimulation
por: Ray, Prasenjit, et al.
Publicado: (2015)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
por: Fujimaki, Koichiro, et al.
Publicado: (2012)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
por: Gilca, Marilena, et al.
Publicado: (2014)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2018)

Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
por: El Khoury, Antoine C., et al.
Publicado: (2020)

Scaling up family planning in Sierra Leone: A prospective cost–benefit analysis
por: Keen, Sarah, et al.
Publicado: (2017)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs
por: Kucharska-Pietura, Katarzyna, et al.
Publicado: (2012)

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics
por: McEvoy, Joseph, et al.
Publicado: (2013)

Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia
por: Shrivastava, Amresh, et al.
Publicado: (2012)

Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
por: Kang, Shi Hyun, et al.
Publicado: (2015)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
por: Chen, Yi-Lung, et al.
Publicado: (2018)

Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
por: Behrouzian, Forouzan, et al.
Publicado: (2022)

Atypical antipsychotics, more than just an antipsychotic
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2020)

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
por: Gharabawi, Georges M, et al.
Publicado: (2007)

Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial
por: Wang, Congjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0g19veqqpijdiu048h0gj6o1rc